4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
RedHill Biopharma Ltd. (RDHL) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Tel Aviv-Yafo, Israel with about 13 employees. Its market capitalization is roughly $4 million. In the fiscal year ended 2025-12-31, RDHL reported $0M in revenue and ($0M) in net income.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Interactive charts & full statements → Open the RDHL valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $62M | — |
| Gross Profit | — | $5M | $3M | $28M | $36M |
| Operating Income (EBIT) | ($8M) | ($6M) | ($10M) | ($43M) | — |
| Net Income | ($0M) | ($8M) | $24M | ($72M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $25M | $18M | $23M | $159M | — |
| Total Liabilities | $21M | $23M | $21M | $207M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RDHL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms